RESUMEN
La prucaloprida acelera el vaciamiento gástrico en adultos con gastroparesia. No existen estudios con este medicamento en niños con gastroparesia. Se presenta un niño de 8 años que consultó por síntomas posprandiales de un mes de duración, con diagnóstico de gastroparesia por gammagrafía de vaciamiento gástrico. No mejoró con metoclopramida, domperidona, eritromicina y esomeprazol. Recibió prucaloprida durante dos períodos (durante 178 y 376 días) a dosis de 0,03-0,04 mg/kg/día. Presentó mejoría en el seguimiento con el índice cardinal de síntomas de gastroparesia y gammagrafías de vaciamiento gástrico. Por la buena respuesta, la prucaloprida podría ser una opción terapéutica en la gastroparesia pediátrica.
Prucalopride has been used in adults with gastroparesis, accelerating gastric emptying. There are no studies with this drug in gastroparetic children. An 8-year-old boy is presented who consulted for a month of postprandial symptoms, with a diagnosis of gastroparesis by gastric emptying scintigraphy. He did not improve with metoclopramide, domperidone, erythromycin, and esomeprazole. He received prucalopride for two periods (for 178 and 376 days) at doses: 0.03 - 0.04 mg/kg/day, presenting improvement in the follow-up with the cardinal gastroparesis symptom index and gastric emptying scintigraphy. Due to the good response, prucalopride may be a therapeutic option in pediatric gastroparesis.
Asunto(s)
Humanos , Masculino , Niño , Benzofuranos/uso terapéutico , Gastroparesia/diagnóstico , Gastroparesia/tratamiento farmacológico , Domperidona/uso terapéutico , Vaciamiento GástricoRESUMEN
Resumen La enfermedad de Chagas es una entidad parasitaria ocasionada por el Tripanosoma cruzi muy prevalente en América, especialmente en América Latina. Su fase indeterminada dura entre 10 a 30 años, período en el que los pacientes no presentan síntomas y pueden emigrar a cualquier parte del mundo. La consecuencia más relevante es la cardiopatía chagásica con diferentes manifestaciones. En muchas ocasiones la manifestación inicial de la cardiopatía es la insuficiencia cardiaca sobre un corazón dilatado lo que en ocasiones hace indispensable descartar un componente isquémico. La gammagrafía de perfusión miocárdica es una herramienta muy útil para el estudio de la cardiopatía isquémica, su alta sensibilidad permite observar defectos de perfusión diversos incluso en ausencia de la enfermedad aterosclerótica coronaria. Presentamos el caso de un paciente con dolor torácico y enfermedad de Chagas con diversos defectos de perfusión de origen microvascular en la gammagrafía de perfusión miocárdica con evidencia de las arterias coronarias epicárdicas sanas.
Abstract Chagas disease is a parasitic entity caused by Tripanosoma cruzi with a high prevalence in America, mostly in Latin America. Its indeterminate phase lasts between 10 and 30 years. Within this period patients do not show symptoms and can migrate to anywhere in the world. The most relevant consequence is chagasic cardiomyopathy with different manifestations. Many times the initial sign of this cardiomyopathy is cardiac insufficiency in a dilated heart, which on occasion makes it imperative to rule out an ischemic component. Myocardial perfusión scintigraphies are a useful tool to study myocardial ischemia, their high sensitivity allows to observe diverse perfusion defects, even in the absence of atherosclerotic coronary disease. This study presents the case of a male patient with chest pain and Chagas disease showing multiple perfusion defects of microvascular origin in the myocardial perfusion scintigraphy, evidencing healthy epicardial coronary arteries.
Asunto(s)
Humanos , Enfermedad de Chagas , Cardiomiopatías , Medicina Nuclear , RadioisótoposRESUMEN
Objective: This study sought to determine the relationship between the results obtained from myocardial SPECT with pharmacologic stress with dipyridamole and the development of major cardiovascular events in the follow-up of patients treated at two nuclear medicine departments in Bogota, Colombia. Materials and methods: 183 patients undergoing myocardial SPECT with pharmacological stress with dipyridamole between November 2011 and April 2012 with a twelve month follow-up, were included. The relationship between the development of major cardiovascular events and the functional or perfusion results of the myocardial SPECT were analyzed. Results: 14 patients from the 154 who completed the follow-up, developed cardiovascular events. Patients with abnormal studies had higher number of events (13 vs 1. p = 0.019) compared to those with normal studies. The results of abnormal perfusion were associated with higher incidence of events (15.19%). Conclusions: A normal myocardial SPECT study is related to reduced incidence of major cardiovascular events in a one year follow-up, even in patients with high-risk clinical characteristics.
Objective: This study sought to determine the relationship between the results obtained from myocardial SPECT with pharmacologic stress with dipyridamole and the development of major cardiovascular events in the follow-up of patients treated at two nuclear medicine departments in Bogota, Colombia. Materials and methods: 183 patients undergoing myocardial SPECT with pharmacological stress with dipyridamole between November 2011 and April 2012 with a twelve month follow-up, were included. The relationship between the development of major cardiovascular events and the functional or perfusion results of the myocardial SPECT were analyzed. Results: 14 patients from the 154 who completed the follow-up, developed cardiovascular events. Patients with abnormal studies had higher number of events (13 vs 1. p = 0.019) compared to those with normal studies. The results of abnormal perfusion were associated with higher incidence of events (15.19%). Conclusions: A normal myocardial SPECT study is related to reduced incidence of major cardiovascular events in a one year follow-up, even in patients with high-risk clinical characteristics.